Tagged with EG

Canada Hydropothecary is the leading medicinal cannabis producer in Quebec, founded in 2013 by two brothers-in-law, Sebastien St-Louis and Adam Miron. Terry Lake, former Minister of Health for British Colombia, discusses his new role as Vice President Corporate Social Responsibility, the stigma surrounding the cannabis plant and how to bring innovative…

Baltics Evija Buksa, general manager at Merck in Latvia, explains the strong history of Merck in the country as well as its key role in participating in the discussions to shape the Latvian healthcare system. Could you please start by introducing Merck in Latvia and the strategic significance of the local…

Ecuador Juan Carlos Galarza, executive director of Ecuador’s National Health Regulation, Control and Surveillance Agency (ARCSA), discusses the multiple procedural improvements that the Agency has recently implemented with the objective of increasing its international recognition, the benefits of these actions for Ecuadorians – who will have faster and safer access to…

Poland Dorota Hryniewiecka-Firlej, president of Pfizer Poland, discusses the current state of the Polish innovation landscape and importance of a tight-knit relationship between the innovative pharmaceutical market and the government for better patient outcomes. Furthermore, she highlights the strong R&D footprint of Pfizer Poland and their role in facilitating a domestic…

Brazil “Brazil undoubtedly holds great development opportunities for the global pharmaceutical and healthcare industries,” boldly states Minister of Health Ricardo Barros, “and we hope to gain the trust of an increasing number of international investors and jointly work on improving the healthcare products and services available to our 207 million Brazilian…

Baltics SIFFA’s Valters Bolēvics discusses Latvia’s competitiveness in embracing medical innovations, current healthcare reforms, and the country’s enduring potential as a pharmaceutical investment destination. The Association of International Research-based Pharmaceutical Manufacturers (SIFFA) was initially founded in 1996 to act as a united voice for five multinationals that had penetrated the local…

Poland Robert Bitner, country manager of Galderma Poland, give his first impressions of the Polish dermatology landscape and how his past experiences have prepared him for the challenges ahead. Additionally, he highlights the importance of establishing strong partnerships with Polish medical personnel for long-term success and the potential of the company’s…

India For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India still stands as a land of opportunity for a variety of reasons. Novartis India country president Jawed Zia points out that “India, in terms of demographics, is the youngest nation in the world. The…

India Umang Vohra, managing director and global CEO of Indian pharma giant Cipla, discusses the company’s ambition to grow in both the domestic and emerging markets as well as the opportunities that Cipla sees as a specialty pharmaceutical company in the US.   The opportunity to service such a vast patient…

Baltics Janis Silins of the Association of Biopharmaceutical Drug Manufacturers in Latvia discusses the organization’s purpose, collaboration efforts, and role in shaping policy reform. Could you please start by introducing the Association of Biopharmaceutical Drug Manufacturers in Latvia (Biofarmaceitisko Ražotāju Asociācijas Latvijā (BRAL)) and your role within the association? “We strive…

Canada Jaiveer Singh, CEO of Mint Pharmaceuticals explains the company’s business model and how it fits the characteristics of the Canadian market on the tenth anniversary of the company. He further highlights how Mint’s portfolio of boutique generics is sure to grow over the coming years to meet the specific needs…

Serbia Between 2010 and 2012 just one of the 139 new medicines to receive market authorisations globally was approved for reimbursement in Serbia, compared with 44 in Bulgaria and 27 in Croatia; meaning a severe lack of patient access to much-needed treatments as well as an extremely challenging environment for innovative…